EE273 Cost-Effectiveness of Rozanolixizumab vs. Efgartigimod in the Treatment of Generalized Myasthenia Gravis (gMG) in Greece
Abstract
Authors
CHRISTINA GOLNA Pavlos Golnas Michael Feretos Sergei Kalynych Ramona SCHMID Hicham Benhaddi Vasilios K. Kimiskidis Kyriakos Souliotis